Data Expanded for Oncology, Neurology and Urology; Initiated for
Dermatology and OB/GYN
MOUNT LAUREL, N.J., Nov. 2 /PRNewswire/ -- ImpactRx, Inc., the pioneering force in measuring the impact of pharmaceutical promotion on physicians' prescribing behavior, announced today that it is expanding its nationwide physician information networks in alignment with emerging market trends and rising client demand. ImpactRx is increasing the size of its longitudinal, smartphone-enabled physician research panels in three key specialties, and is initiating data collection in two additional specialties to broaden the scope of its data and services.
ImpactRx recently increased the size of its neurology specialty panel by 50 percent, is completing a similar-sized increase to its panel of urologists, and plans to expand its groundbreaking oncology research panel beginning in the first quarter of 2008.
"The oncology market has become increasingly competitive as the availability of new treatment alternatives grows and companies promote more aggressively for a share of the oncologist's attention," said Jill Walton, recently appointed Managing Director and Vice President of ImpactRx's Oncology Business Unit. "Clients need to accurately assess performance, and ImpactRx's point-of-promotion and point-of-treatment model provides unmatched insight into sales execution and effectiveness. This expansion enhances our ability to provide our clients with the information edge needed to compete and win in the oncology marketplace," said Walton.
In addition to expanding its existing physician panels, ImpactRx is adding new panels for two important specialties, dermatologists and obstetricians/gynecologists.
"This extension of our information networks puts us in a stronger
position to support trends emerging across our customer base," said John
Kain, ImpactRx's Vice President of Marketing. "We will be much better
situated to support
|SOURCE ImpactRx, Inc.|
Copyright©2007 PR Newswire.
All rights reserved